XITRIENE
PRANLUKAST DRY SYRUP 10% W/W
What it does
Pranlukast is a medication that helps manage asthma by relaxing the airways, making it easier to breathe.
Commonly used for: asthma, exercise-induced bronchospasm
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.
Source this medicineRegistration & product details
Source: Pharmacy and Poisons Board · fetched 2026-01-28 20:30:48 · updated 2026-10-20 02:30:13
About this medicine
Pranlukast is a medication that helps manage asthma by relaxing the airways, making it easier to breathe.
What it treats
- asthma
- exercise-induced bronchospasm
How it works
Pranlukast works by blocking certain substances in your body that cause inflammation and tightening of the airways.
Who it's for
This medication is for people with asthma or those who experience breathing difficulties during exercise.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: pranlukast
BNF-referencedPranlukast is a selective antagonist of the cysteinyl leukotriene receptor-1 (CysLT1) used primarily in the management of asthma. By inhibiting leukotriene D4 (LTD4) at the CysLT1 receptor, it plays a significant role in reducing airway inflammation, preventing bronchoconstriction, and decreasing mucus production, thereby improving respiratory function in patients with asthma.
Indications
- Asthma
- Allergic rhinitis
Dosage
Children: Refer to the BNF for Children for specific dosing guidelines for paediatric patients.
Adults: Refer to the BNF for specific dosing guidelines for adults.
Mechanism of action
Pranlukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. This inhibition prevents airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
Pharmacodynamics
Pranlukast is classified as a cysteinyl leukotriene receptor-1 antagonist, which contributes to its therapeutic effects in reducing bronchoconstriction and inflammation in the airways.
Pharmacokinetics
The pharmacokinetics of pranlukast include its absorption, distribution, metabolism, and excretion, although specific parameters such as half-life and clearance are not provided here. It is important to refer to detailed pharmacokinetic studies for comprehensive information.
Pregnancy
There are no adequate and well-controlled studies in pregnant women. Pranlukast should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Breast-feeding
It is not known whether pranlukast is excreted in human milk. Caution should be exercised when administering to nursing women.
Storage
Store in a cool, dry place away from direct light. Keep out of reach of children.
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Molecular reference: pranlukast
PubChem CID 4887Molecular formula: C27H23N5O4
Mechanism of action
Pranlukast selectively antagonizes leukotriene D<sub>4</sub> (LTD<sub>4</sub>) at the cysteinyl leukotriene receptor, CysLT<sub>1</sub>, in the human airway. Pranlukast inhibits the actions of LTD<sub>4</sub> at the CysLT<sub>1</sub> receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
Pharmacodynamics
Pranlukast is a cysteinyl leukotriene receptor-1 antagonist.
Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.